We are analyzing https://link.springer.com/article/10.1007/s00401-013-1106-9.

Title:
What do we know about IDH1/2 mutations so far, and how do we use it? | Acta Neuropathologica
Description:
Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, pubmed, cas, idh, mutations, gliomas, mutation, cancer, isocitrate, glioma, dehydrogenase, neuropathol, acta, oncol, molecular, patients, brain, prognostic, pathol, hydroxyglutarate, leukemia, glioblastoma, res, survival, diffuse, cell, grade, astrocytomas, tumors, analysis, detection, med, cells, clin, article, tumor, nature, park, horbinski, acute, lee, myeloid, neurooncol, kim, study, hartmann, status, lowgrade, neuro,

Topics {✒️}

cold-pcr/fmca assay enhances month download article/chapter idh-mutated low-grade gliomas idh/mgmt-driven molecular classification idh1-mutated low-grade gliomas nadp + -dependent isocitrate dehydrogenase idh1 wild-type gliomas replication-independent nucleosome assembly ischemic pre-conditioned kidney alpha-ketoglutarate-dependent dioxygenases vivo patient-derived model endogenous idh1-mutant glioma low-grade diffuse gliomas progressive low-grade astrocytomas broad-based tumor genotyping paraffin-embedded glioma tissues l-2-hydroxyglutarate dehydrogenase gene ionizing radiation-induced apoptosis low-abundance idh1 mutations tumor necrosis factor-alpha secondary high-grade gliomas unfavorable progression-free survival restriction endonuclease-based detection dependent isocitrate dehydrogenase monoclonal antibody specific isocitrate dehydrogenase mutation idh-mutated glioma patients genomics cancer genetics induces cellular proliferation privacy choices/manage cookies iii diffuse gliomas related subjects lower-grade glioma low-grade glioma mgmt promoter methylation isocitrate dehydrogenase mutations garrett-bakelman fe magnetic resonance spectroscopy de wilde rf full article pdf predict longer survival low-grade astrocytomas nonenhancing diffuse glioma addressing diffuse glioma glioma-derived mutations 1p/19q testing mutant idh1 confers grade ii astrocytomas high grade astrocytomas acute myeloid leukemia

Questions {❓}

DeGregori J (2011) Evolved tumor suppression: why are we so good at not getting cancer?
Duran M, Kamerling JP, Bakker HD, van Gennip AH, Wadman SK (1980) l-2-Hydroxyglutaric aciduria: an inborn error of metabolism?
What do we know about IDH1/2 mutations so far, and how do we use it?
What do we know about IDH1/2 mutations so far, and how do we use it?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:What do we know about IDH1/2 mutations so far, and how do we use it?
         description:Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.
         datePublished:2013-03-20T00:00:00Z
         dateModified:2013-03-20T00:00:00Z
         pageStart:621
         pageEnd:636
         sameAs:https://doi.org/10.1007/s00401-013-1106-9
         keywords:
            IDH1/2
            2-Hydroxyglutarate
            Glioma
            Histone
            Methylation
            Pathology
            Neurosciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig4_HTML.gif
         isPartOf:
            name:Acta Neuropathologica
            issn:
               1432-0533
               0001-6322
            volumeNumber:125
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Craig Horbinski
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Department of Pathology, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:What do we know about IDH1/2 mutations so far, and how do we use it?
      description:Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.
      datePublished:2013-03-20T00:00:00Z
      dateModified:2013-03-20T00:00:00Z
      pageStart:621
      pageEnd:636
      sameAs:https://doi.org/10.1007/s00401-013-1106-9
      keywords:
         IDH1/2
         2-Hydroxyglutarate
         Glioma
         Histone
         Methylation
         Pathology
         Neurosciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00401-013-1106-9/MediaObjects/401_2013_1106_Fig4_HTML.gif
      isPartOf:
         name:Acta Neuropathologica
         issn:
            1432-0533
            0001-6322
         volumeNumber:125
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Craig Horbinski
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Department of Pathology, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Neuropathologica
      issn:
         1432-0533
         0001-6322
      volumeNumber:125
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Kentucky
      address:
         name:Department of Pathology, University of Kentucky, Lexington, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Craig Horbinski
      affiliation:
            name:University of Kentucky
            address:
               name:Department of Pathology, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pathology, University of Kentucky, Lexington, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(390)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.81s.

LINK . SPRINGER . COM {}